Marlise R. Luskin, leukemia specialist at Dana-Farber Cancer Institute, posted on X:
“Severe neutropenia is associated with blinatumomab! Blina is not considered myelosuppressive, but have observed severe neutropenia. We studied 95 pts receiving blina in CR at Dana-Farber Cancer Institute 41% gr≥3 neutropenia, 13% ANC <100, no serious infections, not necessarily recurrent!”
Source: Marlise R. Luskin/X